Compare NWTG & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NWTG | SILO |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Apparel |
| Sector | Consumer Discretionary | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 8.0M |
| IPO Year | N/A | N/A |
| Metric | NWTG | SILO |
|---|---|---|
| Price | $1.46 | $0.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 143.0K | 132.6K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,931,000.00 | $72,102.00 |
| Revenue This Year | $120.41 | $1.86 |
| Revenue Next Year | $70.24 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 178.24 | N/A |
| 52 Week Low | $0.82 | $0.36 |
| 52 Week High | $40.20 | $3.37 |
| Indicator | NWTG | SILO |
|---|---|---|
| Relative Strength Index (RSI) | 45.58 | 36.44 |
| Support Level | $1.62 | $0.42 |
| Resistance Level | $1.74 | $0.46 |
| Average True Range (ATR) | 0.16 | 0.02 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 9.42 | 2.22 |
Newton Golf Co Inc is a technology-forward golf company dedicated to revolutionizing the sport with cutting-edge, high-performance products. The company's expanding portfolio includes golf shafts, putters, grips, and other golf-related accessories designed for golfers of all skill levels. The company sells its products through e-commerce, distributors, wholesale customers, including pro-shops at golf courses and off-course retailers, sporting goods retailers, online retailers, third-party distributors, and through Club Champion Golf, as well as through mass merchants and corporate customers in the Americas, Asia, and Europe.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.